Understanding osteoporosis
Abstract
Osteoporosis is a common skeletal condition that results in significant morbidity, mortality and health care costs. There is an increased awareness of bone health in people with severe mental illness (SMI). These people appear to be at a higher risk of low bone density and fracture, and also have a poorer outcome following hip fracture. The reason for the increased risk of osteoporosis is multifactorial and includes general as well as disease-specific factors, such as antipsychotic medication and hyperprolactinaemia. Clinical history and examination followed by dual energy x-ray absorptiometry are required to assess the risk of osteoporosis. Therapies should begin with lifestyle measures, such as physical activity and dietary supplementation, with the use of bone-specific agents reserved for those at high absolute risk.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The increased risk of osteoporosis in untreated schizophrenia is due to the disease itself and to risk factors related to lifestyle (e.g., smoking, reduced physical activity, alcohol abuse, vitamin D and calcium deficiency, polydipsia).
“On the one hand, this is because of the disease itself, on the other hand, because of risk factors related to their lifestyle (e.g., smoking, reduced physical activity, alcohol abuse, vitamin D and calcium deficiency, polydipsia) (470-476).”
From Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care (2011) · cites this paper as [476]
In comparison with the general population, untreated patients with schizophrenia appear to have an increased risk of developing osteoporosis.
“In comparison with the general population, untreated patients with schizophrenia appear to have an increased risk of developing osteoporosis.”
From Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care (2011) · cites this paper as [476]
Cites
An estimate of the worldwide prevalence and disability associated with osteoporotic fractures
Johnell, O., & Kanis, J. (2006) · Osteoporosis International · doi:10.1007/s00198-006-0172-4 · Cited by 4,770 · see citing works
Age and bone mass as predictors of fracture in a prospective study.
Hui, S. L., Slemenda, C. W., & Johnston, C. C. (1988) · Journal of Clinical Investigation · doi:10.1172/jci113523 · Cited by 1,169 · see citing works
Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas
Casanueva, F. F., Molitch, M. E., Schlechte, J., Abs, R., Bonert, V. S., Bronstein, M. D., Brue, T. C., Cappabianca, P., Colao, A., Fahlbusch, R., et al. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02562.x · Cited by 824 · see citing works
The Treatment of Unrelated Disorders in Patients with Chronic Medical Diseases
Redelmeier, D. A., Tan, S. H., & Booth, G. L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199805213382106 · Cited by 635 · see citing works
Reduced Bone Mass in Daughters of Women with Osteoporosis
Seeman, E., Hopper, J. L., Bach, L. A., Cooper, M. E., Parkinson, E., McKay, J., & Jerums, G. (1989) · New England Journal of Medicine · doi:10.1056/nejm198903023200903 · Cited by 631 · see citing works
Hernandez, C. J., Beaupr�, G. S., & Carter, D. R. (2003) · Osteoporosis International · doi:10.1007/s00198-003-1454-8 · Cited by 570 · see citing works
Bonjour, J. ‐., Carrié, A.-L., Ferrari, S., Clavien, H., Slosman, D. O., Theintz, G. E., & Rizzoli, R. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119287 · Cited by 558 · see citing works
Decreased spinal mineral content in amenorrheic women
Cann, C. E. (1984) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1984.03340290040017 · Cited by 409 · see citing works
Review: developmental origins of osteoporotic fracture
Cooper, C. C., Westlake, S., Harvey, N. C., Javaid, M. K., Dennison, E. M., & Hanson, M. A. (2005) · Osteoporosis International · doi:10.1007/s00198-005-2039-5 · Cited by 385 · see citing works
Self-citationRiggs, B. L., & PARFITT, A. M. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.041114 · Cited by 379 · see citing works
Decreased Bone Density in Hyperprolactinemic Women
Klibanski, A., Neer, R. M., Beitins, I. Z., Ridgway, E. C., Zervas, N. T., & McArthur, J. W. (1980) · New England Journal of Medicine · doi:10.1056/nejm198012253032605 · Cited by 358 · see citing works
SPECKER, B. L., & Binkley, T. L. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.5.885 · Cited by 312 · see citing works
Antipsychotic Drugs: A New Risk Factor for Osteoporosis in Young Women With Schizophrenia?
O'Keane, V., & Meaney, A. M. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000150223.31007.e0 · Cited by 307 · see citing works
Duan, Y., Beck, T., Wang, X., & Seeman, E. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.10.1766 · Cited by 252 · see citing works
Prenatal and childhood influences on osteoporosis
Javaid, M. K., & Cooper, C. C. (2002) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1053/beem.2002.0199 · Cited by 222 · see citing works
Self-citationIncrease in Bone Mass after Treatment of Hyperprolactinemic Amenorrhea
Klibanski, A., & Greenspan, S. L. (1986) · New England Journal of Medicine · doi:10.1056/nejm198608283150903 · Cited by 205 · see citing works
Clément-Lacroix, P., Ormandy, C. J., Lepescheux, L., Ammann, P., Damotte, D., Goffin, V., Bouchard, B., Amling, M., Gaillard-Kelly, M., Binart, N., et al. (1999) · Endocrinology · doi:10.1210/endo.140.1.6436 · Cited by 193 · see citing works
Importance of Gonadal Steroids to Bone Mass in Men with Hyperprolactinemic Hypogonadism
Greenspan, S. L., Oppenheim, D. S., & Klibanski, A. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-110-7-526 · Cited by 190 · see citing works
Anxiolytics, sedatives, antidepressants, neuroleptics and the risk of fracture
Vestergaard, P., Rejnmark, L., & Mosekilde, L. (2006) · Osteoporosis International · doi:10.1007/s00198-005-0065-y · Cited by 187 · see citing works
Alméras, L., Eyles, D. W., Benech, P. D., Laffite, D., Villard, C., Patatian, A., Boucraut, J., Mackay‐Sim, A., McGrath, J. J., & Feron, F. P. (2007) · PROTEOMICS · doi:10.1002/pmic.200600392 · Cited by 186 · see citing works
Dennison, E. M., Mohamed, M. A., & Cooper, C. C. (2006) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2006.08.003 · Cited by 185 · see citing works
Chevalley, T., Rizzoli, R., Hans, D. B., Ferrari, S., & Bonjour, J. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1043 · Cited by 175 · see citing works
Risk of hip fracture in patients with a history of schizophrenia
Howard, L., Kirkwood, G., & Leese, M. (2007) · British Journal of Psychiatry · doi:10.1192/bjp.bp.106.023671 · Cited by 158 · cited 1× · see citing works
“…GPRD), among those with a diagnosis of hip fracture (mean age 79 years, reflecting an older group of patients), there was a higher odds ratio of having a diagnosis of schizophrenia [OR 1.73 (1.32–2.28)] as well as having being prescribed an antipsychotic [OR 2.60 (2.43–2.78)] (Howard et al., 2007).”
BackgroundInfluentialGrafe, I., Fonseca, K. D., Hillmeier, J., Meeder, P., Libicher, M., Nöldge, G., Bardenheuer, H. J., Pyerin, W. G., Basler, L., Weiß, C., et al. (2005) · Osteoporosis International · doi:10.1007/s00198-005-1982-5 · Cited by 154 · see citing works
Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy
Katalinic, A., & Rawal, R. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9566-z · Cited by 149 · see citing works
Burden of osteoporosis and fractures
Keen, R. W. (2003) · Current Osteoporosis Reports · doi:10.1007/s11914-003-0011-x · Cited by 129 · see citing works
Osteoporosis in Patients With Schizophrenia
Hummer, M., Malik, P., Gasser, R. W., Hofer, A., Kemmler, G., Moncayo Naveda, R. C., Rettenbacher, M. A., & Fleischhacker, W. W. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.1.162 · Cited by 125 · see citing works
Becker, D., Liver, O., Mester, R., Rapoport, M., Weizman, A., & Weiss, M. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0704 · Cited by 107 · cited 2× · see citing works
“In cross sectional studies comparing those prescribed olanzapine with those receiving typical prolactin-raising medication, those prescribed olanzipine had lower prolactin concentrations, had higher BMD and were less likely to have menstrual abnormalities (O’Keane and Meaney, 2005; Becker et al., 2003).”
ResultEffects of prolactin on osteoblast alkaline phosphatase and bone formation in the developing rat
Coss, D., Yang, L., Kuo, C. B., Xu, X., Luben, R. A., & Walker, A. M. (2000) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2000.279.6.e1216 · Cited by 102 · see citing works
Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization
Colao, A., Somma, C. D., Loche, S., Sarno, A. D., Klain, M., Pivonello, R., Pietrosante, M., Salvatore, M., & Lombardi, G. (2000) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2000.00902.x · Cited by 101 · see citing works
Howes, O. D., Wheeler, M. J., Pilowsky, L. S., Landau, S., Murray, R. M., & Smith, S. M. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0302 · Cited by 93 · see citing works
Vertebral Body Bone Mineral Content in Hyperprolactinemic Women
KOPPELMAN, M. C. S., Kurtz, D., Morrish, K. A., Bou, E., SUSSER, J. K., Shapiro, J. R., & Loriaux, D. L. (1984) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-59-6-1050 · Cited by 93 · see citing works
Bowman, B. M., Siska, C. C., & Miller, S. C. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.11.1954 · Cited by 65 · see citing works
Delva, N. J., Crammer, J., Jarzylo, S., Lawson, J. S., Owen, J. A., Sribney, M., Weir, B., & Yendt, E. R. (1989) · Biological Psychiatry · doi:10.1016/0006-3223(89)90119-4 · Cited by 59 · see citing works
Hormone Replacement Therapy and Cardioprotection
Rosano, G. M. C., Vitale, C., & Fini, M. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1365.031 · Cited by 55 · see citing works
Bone mineral density and prolactin associations in patients with chronic schizophrenia
Abraham, G., Halbreich, U. M., Friedman, R. H., & Josiassen, R. C. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(01)00321-8 · Cited by 48 · see citing works
Receptor activator of nuclear factor κB ligand (RANKL): another link between breast and bone
Martin, T. J., & Gillespie, M. T. (2001) · Trends in Endocrinology and Metabolism · doi:10.1016/s1043-2760(00)00351-9 · Cited by 43 · see citing works
Prevalence of Bone Mineral Density Loss in Korean Patients With Schizophrenia
Jung, D.-U., Conley, R. R., Kelly, D. L., Kim, D., Yoon, S.-H., Jang, J.-H., Shin, J.-G., & Shim, J.-C. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0909 · Cited by 43 · see citing works
Adverse outcome of hip fractures in older schizophrenic patients
Yarden, P. E., Finkel, M. G., Raps, C. S., & Girvan, J. J. (1989) · American Journal of Psychiatry · doi:10.1176/ajp.146.3.377 · Cited by 17 · see citing works
Decreased bone mineral density in male schizophrenia patients
Lehman, D., & Meyer, J. M. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.12.004 · Cited by 11 · see citing works
Puntheeranurak, S., Charoenphandhu, N., & Krishnamra, N. (2006) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y06-047 · Cited by 11 · see citing works
Bone mineral density and prolactin associations in patients with chronic schizophrenia
Howes, O. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(03)00054-9 · Cited by 3 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
DE HERT, M., CORRELL, C. U., BOBES, J., CETKOVICH‐BAKMAS, M., COHEN, D., ASAI, I., DETRAUX, J., GAUTAM, S., MÖLLER, H., NDETEI, D. M., et al. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00014.x · Cited by 2,488 · see citing works
Peuskens, J., Pani, L., Detraux, J., & De Hert, M. (2014) · CNS Drugs · doi:10.1007/s40263-014-0157-3 · Cited by 350 · see citing works
O'Keane, V. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107088439 · Cited by 126 · see citing works
Osteoporosis and fracture risk in people with schizophrenia
Kishimoto, T., Binder, M. D., Carlson, H. E., Manu, P., & Correll, C. U. (2012) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e328355e1ac · Cited by 116 · see citing works
Schizophrenia and the risk of fractures: a systematic review and comparative meta-analysis
Stubbs, B., Gaughran, F., Mitchell, A. J., Binder, M. D., Farmer, R., Soundy, A., Rosenbaum, S., & Vancampfort, D. (2015) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2015.01.004 · Cited by 100 · see citing works
Adverse Endocrine and Metabolic Effects of Psychotropic Drugs
Bhuvaneswar, C. G., Baldessarini, R. J., Harsh, V., & Alpert, J. E. (2009) · CNS Drugs · doi:10.2165/11530020-000000000-00000 · Cited by 96 · see citing works
A meta-analysis of prevalence estimates and moderators of low bone mass in people with schizophrenia
Stubbs, B., De Hert, M., Sepehry, A. A., Correll, C. U., Mitchell, A. J., Soundy, A., Detraux, J., & Vancampfort, D. (2014) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12313 · Cited by 92 · see citing works
The role of interleukin-6 in rheumatoid arthritis-associated osteoporosis
Edwards, C., & Williams, E. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1192-7 · Cited by 90 · see citing works
Binder, M. D., Detraux, J., & Stubbs, B. (2016) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1167873 · Cited by 79 · see citing works
Olanzapine: review of safety 2008
Kantrowitz, J. T., & Citrome, L. (2008) · Expert Opinion on Drug Safety · doi:10.1517/14740330802423234 · Cited by 62 · see citing works
Effects of Antipsychotics on Bone Mineral Density in Patients with Schizophrenia: Gender Differences
Chen, C., Lane, H., & Lin, C. (2016) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2016.14.3.238 · Cited by 56 · see citing works
Wang, M., Hou, R. H., Jia, J., Mi, G., Qiu, H.-M., Cao, B., & Tang, M. (2014) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2387 · Cited by 51 · see citing works
Bone Loss Associated with Hyperprolactinemia in Patients with Schizophrenia
Kinon, B. J., Liu‐Seifert, H., Stauffer, V. L., & Jacob, J. (2013) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.kise.020113 · Cited by 44 · see citing works
Walters, J., & Jones, I. D. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107086516 · Cited by 39 · see citing works
The nutritional significance of cheese in the UK diet
ASH, A. S. F., & WILBEY, R. A. (2010) · International Journal of Dairy Technology · doi:10.1111/j.1471-0307.2010.00606.x · Cited by 34 · see citing works
Affective Disorders, Bone Metabolism, and Osteoporosis
Mezuk, B. R. (2008) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1007/s12018-009-9025-y · Cited by 25 · see citing works
D2 dopamine receptor gene (DRD2) Taq1A (rs1800497) affects bone density
Chiang, T.-I., Lane, H., & Lin, C. (2020) · Scientific Reports · doi:10.1038/s41598-020-70262-0 · Cited by 16 · see citing works
Li, S., Chen, X., Qiu, Y., Teng, Z., Xu, X., Tang, H., Xiang, H., Wang, B., Chen, J., Yuan, H., et al. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.12.066 · Cited by 11 · see citing works
Polyphenol Antioxidants and Bone Health: A Review
RAO, L. G. S., Kang, N., & Rao, A. V. (2012) · InTech eBooks · doi:10.5772/39287 · Cited by 9 · see citing works
Osteoporosis in people with severe mental illness: A forgotten condition
Holt, R. I. G. (2010) · Maturitas · doi:10.1016/j.maturitas.2010.06.004 · Cited by 8 · see citing works
Self-citationManavi, B. A., Corney, K. B., Mohebbi, M., Quirk, S. E., Stuart, A. L., Pasco, J. A., Hodge, J. M., Berk, M., & Williams, L. J. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-02884-1 · Cited by 7 · see citing works
Karki, A., & Wu, J. (2022) · Acoustics · doi:10.3390/acoustics4020025 · Cited by 4 · see citing works
Ewees, A. A., Elaziz, M. A., Arafa, R. M., & Ghoniem, R. M. (2020) · IEEE Access · doi:10.1109/access.2020.3036831 · Cited by 5 · see citing works
Hiperprolactinemia y tratamiento antipsicótico. Manifestaciones clínicas y manejo
Rubio‐Abadal, E., & Usall, J. (2013) · Psiquiatría Biológica · doi:10.1016/j.psiq.2013.06.011 · Cited by 2 · see citing works
Is swimming able to maintain bone health and to minimize postmenopausal bone resorption?
Barreto, T. K. D. P., Bizarria, F. S., Coutinho, M. P. G., Silveira, P. V. D. C., da Silva, K. D. C., Esteves, A. C. F., & de Moraes, S. R. A. (2014) · Revista Brasileira de Reumatologia (English Edition) · doi:10.1016/j.rbre.2014.03.005 · Cited by 2 · see citing works
Zhovner, M., Kalinkevich, A. N., Danilchenko, S. N., Kuznetsov, V. N., Wang, J., Li, H., He, J., & Feng, X. (2020) · Experimental Techniques · doi:10.1007/s40799-020-00380-x · Cited by 2 · see citing works
A natação é capaz de manter a saúde do tecido ósseo e minimizar a reabsorção óssea pós-menopausa?
Barreto, T. K. D. P., Bizarria, F. S., Coutinho, M. P. G., Silveira, P. V. D. C., da Silva, K. D. C., Esteves, A. C. F., & de Moraes, S. R. A. (2014) · Revista Brasileira de Reumatologia · doi:10.1016/j.rbr.2014.03.005 · Cited by 1 · see citing works
Ibrahem, E., Mohamed, G. A. E., & gazar, A. E. (2022) · Egyptian Journal of Chemistry · doi:10.21608/ejchem.2022.127817.5699
- Authors
- Javaid, M. K., & Holt, R. I.
- Affiliations
- University of Southampton (GB)
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2008-03
- Volume
- 22
- Issue
- 2_suppl
- Pages
- 38-45
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W4249016253
- Cited by
- 28
- References
- 43
- Citations by year
- 2024: 1 · 2023: 1 · 2022: 2 · 2020: 3 · 2016: 2 · 2015: 1 · 2014: 5 · 2013: 2 · 2012: 2
- FWCI
- 0.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Keywords
- osteoporosis, severe mental illness, osteopenia, fracture risk, hip fracture outcomes, antipsychotic drugs, hyperprolactinemia, dual-energy X-ray absorptiometry, bone health, physical activity, dietary supplementation
- MeSH terms
- Mental Disorders, Humans, Hyperprolactinemia, Osteoporosis, Risk Factors, Antipsychotic Agents, Risk Assessment, Fractures, Bone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
